Healthcare
Live Price
Offline$25.59
+0.08% today
1Y Change
—
Window
No data
Historical coverage is still loading
We are still backfilling 1Y daily history for this symbol. Some charts may stay empty until more data arrives.
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Deciphera Pharmaceuticals, Inc. (DCPH) is a Healthcare stock with a market cap of $2.21B. The stock last traded around $25.59. Baseline metrics include revenue growth of +21.9%, EPS growth of +3.4%, a dividend yield of 0.0%. What stands out right now is revenue +21.9%, EPS +3.4%, free cash flow +4.1% with operating margin -129.1% and ROIC -56.0%. Valuation already assumes a fairly strong business story at price/sales 13.5. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines DCPH price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
DCPH
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
DCPH Max Drawdown
—
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for DCPH and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$25.0M
-40.6% YoY
FY Net Income
-$191.5M
+28.1% YoY
Free Cash Flow
-$154.2M
+37.0% YoY
Revenue Growth
+21.9%
EPS Growth
+3.4%
Gross Margin
97.7%
Net Margin
-119.3%
Income statement
USD
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 163M | 134M | 96M | 42M | 25M |
| Gross Profit | 160M | 125M | 93M | 42M | 24M |
| Operating Income | -211M | -183M | -300M | -271M | -201M |
| EBITDA | -209M | -171M | -297M | -264M | -184M |
| Net Income | -195M | -179M | -297M | -266M | -191M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Cash & Equivalents | 84M | 65M | 87M | 136M | 120M |
| Total Assets | 474M | 454M | 429M | 642M | 622M |
| Total Liabilities | 123M | 112M | 125M | 99M | 76M |
| Shareholder Equity | 351M | 342M | 305M | 544M | 546M |
| Total Debt | 26M | 29M | 31M | 31M | 18M |
| Net Debt | -58M | -36M | -56M | -105M | -103M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
149M
+37.7% YoY
Capital Expenditures
5M
+7.2% YoY
Free Cash Flow
154M
+37.0% YoY
Key ratios
Gross Margin
97.7%
Operating Margin
-129.1%
Net Margin
-119.3%
ROE
-56.3%
Debt / Equity
0.07x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.